Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Incyte: Riding Jakafi, Bracing For Generic Headwinds
01:11am, Thursday, 27'th Nov 2025
Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura sa
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 20'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Incyte (INCY) is a Top Value Stock for the Long-Term
10:46am, Wednesday, 19'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte to Present at Upcoming Investor Conferences
08:00am, Wednesday, 19'th Nov 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of December: Citi's 2025 Global Healthcare Conferenc
Incyte Corporation (INCY) Presents at Jefferies London Healthcare Conference 2025 Transcript
01:48pm, Tuesday, 18'th Nov 2025
Incyte Corporation ( INCY ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
04:05pm, Monday, 17'th Nov 2025
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL).
Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
01:51pm, Monday, 10'th Nov 2025
Incyte Corporation ( INCY ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnon
Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
09:15am, Thursday, 06'th Nov 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema.
Top Biotech Stocks Riding The Rally
03:15pm, Tuesday, 04'th Nov 2025
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock pric
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
07:01am, Tuesday, 04'th Nov 2025
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
09:31am, Monday, 03'rd Nov 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting.
Bessemer Group Inc. Reduces Stock Holdings in Incyte Corporation $INCY
03:35am, Monday, 03'rd Nov 2025
Bessemer Group Inc. reduced its stake in Incyte Corporation (NASDAQ: INCY) by 60.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissi
Incyte to Present at Upcoming Investor Conferences
08:00am, Thursday, 30'th Oct 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation
4 Best Value And Growth Stocks (Yes, They Can Coexist)
08:00am, Thursday, 30'th Oct 2025
The current market is all about momentum, but investors don't need to buy overpriced high-growth stocks to participate in gains. If you dig deep enough, you can find undervalued stocks with growth pot
